论文部分内容阅读
目的:探讨α-晶状体蛋白B链(Alpha-crystallin B chain,CRYAB)在乳腺癌中表达的临床病理学意义。方法:收集乳腺癌病例及相应的临床资料包括随访资料,应用IHC染色方法检测CRYAB在乳腺良性病变(BBD)、无淋巴结转移乳腺癌(NMBC)、有淋巴结转移乳腺癌(MBC)及配对淋巴结转移灶(PMLN)中的表达,分析CRYAB表达与乳腺癌临床病理指标(患者年龄、肿块大小、淋巴结转移情况、临床分期、组织学分型和分级、雌孕激素受体和c-cerb B2表达情况、绝经情况)间及生存状态的关系。结果:CRYAB在对照组BBD组、NMBC组、MBC组、PMLN组的阳性表达率分别为97.9%(46/47)、44.6%(37/83)、13.1%(14/107)、10.8%(11/107),其中BBD组和NMBC组,BBD组、NMBC组分别与MBC组、PMLN组均存在显著性差异。CRYAB表达与淋巴结转移(P<0.001)、临床分期(P=0.001)、组织学分级(P=0.037)和雌孕激素受体表达情况(P<0.001)有显著相关,无淋巴结转移组的阳性表达率显著高于有淋巴结转移组,临床晚期的阳性表达率低于临床早期,雌孕激素受体阳性病例的阳性表达率显著低于雌孕激素受体阴性病例。生存分析结果显示CRYAB阳性表达的患者生存期比CRYAB阴性表达的患者生存期更长(p=0.037)。结论:CRYAB与乳腺癌的转移、临床分期、生存状态、雌孕激素受体表达有关。
Objective: To investigate the clinicopathological significance of alpha-crystallin B chain (CRYAB) expression in breast cancer. Methods: The cases of breast cancer and corresponding clinical data including follow-up data were collected. IHC staining was used to detect the expression of CRYAB in benign breast lesions (BBD), non-lymph node metastatic breast cancer (NMBC), lymph node metastatic breast cancer (MBC) and matched lymph node metastasis (PMLN), and analyze the relationship between CRYAB expression and clinicopathological parameters (age, size, lymph node metastasis, clinical stage, histological classification and classification, estrogen-progesterone receptor and c-cerb B2 expression in breast cancer, Menopause) and the relationship between the state of existence. Results: The positive expression rates of CRYAB in control group were 97.9% (46/47), 44.6% (37/83), 13.1% (14/107) and 10.8% (P <0.05) respectively in BBD group, NMBC group, MBC group and PMLN group 11/107). BBD group, NMBC group, BBD group and NMBC group had significant differences with MBC group and PMLN group respectively. CRYAB expression was significantly associated with lymph node metastasis (P <0.001), clinical stage (P = 0.001), histological grade (P = 0.037) and estrogen and progestogen receptor expression (P <0.001) The expression rate was significantly higher than that in patients with lymph node metastasis. The positive expression rate in late clinical stage was lower than that in early clinical stage. The positive rate of estrogen and progesterone receptor positive cases was significantly lower than that of estrogen and progesterone receptor negative cases. Survival analysis showed that CRYAB-positive patients had longer survival than patients with CRYAB-negative expression (p = 0.037). Conclusion: CRYAB is related to the metastasis, clinical stage, survival status and the expression of estrogen and progesterone receptors in breast cancer.